AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
fluphenazine decanoate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1213 | 5002-47-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 2.70 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 4.934 | Moderate | 0.67 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.575 | Moderate | 0.67 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.008 | 10^-6 cm/s | Moderate | 0.67 |
| dh-clint | Dog hepatocyte intrinsic clearance | 56.105 | uL/min/10^6 cells | Moderate | 0.67 |
| dppb | Dog plasma protein binding (% unbound) | 0.130 | % | Moderate | 0.67 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 0.020 | % | Moderate | 0.67 |
| herg | hERG pIC50 | 5.138 | pIC50 | Moderate | 0.67 |
| hh-clint | Human hepatocyte intrinsic clearance | 81.658 | uL/min/10^6 cells | Moderate | 0.67 |
| hlm-clint | Human liver microsomal intrinsic clearance | 220.293 | uL/min/mg protein | Moderate | 0.67 |
| hppb | Human plasma protein binding (% unbound) | 0.210 | % | Moderate | 0.67 |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.151 | Moderate | 0.67 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 132.130 | Moderate | 0.67 | |
| mppb | Mouse plasma protein binding (% unbound) | 0.210 | Moderate | 0.67 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.072 | Moderate | 0.67 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 1 | |||
| pppb | Pig plasma protein binding (% unbound) | 0.150 | % | Moderate | 0.67 |
| rh-clint | Rat hepatocyte intrinsic clearance | 80.538 | uL/min/10^6 cells | Moderate | 0.67 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 0.060 | % | Moderate | 0.67 |
| rppb | Rat plasma protein binding (% unbound) | 0.110 | % | Moderate | 0.67 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 0.347 | uM | Moderate | 0.67 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 20, 1972 | FDA | BRISTOL MYERS SQUIBB |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Neuroleptic malignant syndrome | 109.91 | 44.55 | 30 | 552 | 21442 | 42599311 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Neuroleptic malignant syndrome | 152.82 | 38.61 | 39 | 913 | 34020 | 110554327 |
| Delusion | 45.47 | 38.61 | 14 | 938 | 23741 | 110564606 |
| Accommodation disorder | 42.92 | 38.61 | 7 | 945 | 646 | 110587701 |
| Sedation | 40.60 | 38.61 | 17 | 935 | 69666 | 110518681 |
| Blood prolactin increased | 39.84 | 38.61 | 9 | 943 | 4633 | 110583714 |
| Drug interaction | 38.95 | 38.61 | 33 | 919 | 500150 | 110088197 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA CS | M0016525 | Phenothiazines |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014149 | Tranquilizing Agents |
| MeSH PA | D014150 | Antipsychotic Agents |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018492 | Dopamine Antagonists |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:37930 | phenothiazine antipsychotic drug |
| CHEBI has role | CHEBI:48561 | dopaminergic antagonist |
| CHEBI has role | CHEBI:149553 | anticoronaviral agent |
| CHEBI has role | CHEBI:50266 | prodrug |
| CHEBI has role | CHEBI:50748 | antipsoriatic |
| FDA EPC | N0000175746 | Phenothiazine |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Schizophrenia | indication | 58214004 | DOID:5419 |
| Psychotic disorder | indication | 69322001 | |
| Alcoholism | contraindication | 7200002 | |
| Organophosphate poisoning | contraindication | 8260003 | |
| Weight gain finding | contraindication | 8943002 | |
| Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
| Senile dementia | contraindication | 15662003 | |
| Chronic disease of respiratory system | contraindication | 17097001 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Orthostatic hypotension | contraindication | 28651003 | |
| Torsades de pointes | contraindication | 31722008 | |
| Parkinsonism | contraindication | 32798002 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Chronic heart failure | contraindication | 48447003 | |
| Bradycardia | contraindication | 48867003 | |
| Extrapyramidal disease | contraindication | 76349003 | |
| Hyperglycemia | contraindication | 80394007 | DOID:4195 |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Stupor | contraindication | 89458003 | |
| Tardive dyskinesia | contraindication | 102449007 | |
| Prolonged QT interval | contraindication | 111975006 | |
| Acute disease of cardiovascular system | contraindication | 128487001 | |
| Angina pectoris | contraindication | 194828000 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Metabolic syndrome X | contraindication | 237602007 | DOID:14221 |
| Hyperprolactinemia | contraindication | 237662005 | DOID:12700 |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Retention of urine | contraindication | 267064002 | |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Coma | contraindication | 371632003 | |
| At risk for aspiration | contraindication | 371736008 | |
| Visual impairment | contraindication | 397540003 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
| Obesity | contraindication | 414916001 | DOID:9970 |
| Congenital long QT syndrome | contraindication | 442917000 | |
| Carcinoma of female breast | contraindication | 447782002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.85 | Basic |
| pKa2 | 3.85 | Basic |
| pKa3 | 2.72 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| D(2) dopamine receptor | GPCR | ANTAGONIST | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4017722 | VUID |
| N0000179137 | NUI |
| D00793 | KEGG_DRUG |
| 4017722 | VANDF |
| 4019762 | VANDF |
| C0060580 | UMLSCUI |
| CHEBI:5124 | CHEBI |
| CHEMBL1200854 | ChEMBL_ID |
| C011825 | MESH_SUPPLEMENTAL_RECORD_UI |
| FMU62K1L3C | UNII |
| 3388 | PUBCHEM_CID |
| 25190 | RXNORM |
| 3881 | MMSL |
| 4697 | MMSL |
| 4748 | MMSL |
| d00237 | MMSL |
| 001473 | NDDF |
| 001474 | NDDF |
| 372730004 | SNOMEDCT_US |
| 396063006 | SNOMEDCT_US |
| 41365009 | SNOMEDCT_US |
| D005476 | MESH_DESCRIPTOR_UI |
| C0016368 | UMLSCUI |
| DB00623 | DRUGBANK_ID |
| 3372 | PUBCHEM_CID |
| 946 | INN_ID |
| CHEBI:5123 | CHEBI |
| FMU62K1L3C | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Fluphenazine Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9529 | INJECTION | 25 mg | INTRAMUSCULAR | ANDA | 14 sections |
| Fluphenazine Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-838 | INJECTION, SOLUTION | 25 mg | INTRAMUSCULAR | ANDA | 17 sections |
| Fluphenazine Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-129 | INJECTION, SOLUTION | 25 mg | INTRAMUSCULAR | ANDA | 17 sections |
| Fluphenazine Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-129 | INJECTION, SOLUTION | 25 mg | INTRAMUSCULAR | ANDA | 17 sections |
| FLUPHENAZINE DECANOATE | Human Prescription Drug Label | 1 | 55150-267 | INJECTION, SOLUTION | 125 mg | INTRAMUSCULAR | ANDA | 11 sections |
| FLUPHENAZINE DECANOATE | Human Prescription Drug Label | 1 | 55150-267 | INJECTION, SOLUTION | 125 mg | INTRAMUSCULAR | ANDA | 11 sections |
| Fluphenazine Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-272 | INJECTION, SOLUTION | 25 mg | INTRAMUSCULAR | ANDA | 11 sections |
| Fluphenazine Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64725-0272 | INJECTION, SOLUTION | 25 mg | INTRAMUSCULAR | ANDA | 11 sections |
| Fluphenazine Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-359 | INJECTION, SOLUTION | 25 mg | INTRAMUSCULAR | ANDA | 14 sections |
| fluphenazine decanoate | Human Prescription Drug Label | 1 | 68083-476 | INJECTION, SOLUTION | 25 mg | INTRAMUSCULAR | ANDA | 15 sections |
| Fluphenazine Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72162-2635 | INJECTION, SOLUTION | 25 mg | INTRAMUSCULAR | ANDA | 11 sections |
| Fluphenazine Decanoate | Human Prescription Drug Label | 1 | 72205-100 | INJECTION, SOLUTION | 25 mg | INTRAMUSCULAR | ANDA | 11 sections |